Search

Antidepressant response is a multifactorial process related to biological and environmental factors, where brain-derived neurotrophic factor (BDNF) may play an important role in modulating depressive and anxious symptoms. We aimed to analyze how BDNF impacts antidepressant response, considering the levels of anxiety. Methods: A total of 40 depressed adults were included. We evaluated initial serum BDNF, anxiety through the State–Trait Anxiety Inventory (STAI), and the severity of depressive symptoms by the Hamilton Depression Rating Scale (HDRS). Participants received antidepressant treatment for 8 weeks, and response to treatment was evaluated according to the final HDRS scores. Results: Basal BDNF was higher in responders compared to non-responder depressed patients, in addition to being inversely associated with the severity of anxiety and depression. Conclusions: Baseline BDNF serum is an adequate predictive factor for response to antidepressant treatment with SSRI, with lower pre-treatment levels of BDNF associated with higher anxiety symptoms after treatment. Stress levels could influence the response to treatment, but its association was not conclusive. [ABSTRACT FROM AUTHOR]

Copyright of Revista Internacional de Investigación en Adicciones is the property of Centros de Integracion Juvenil A.C. (CIJ) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Salud Mental is the property of Instituto Nacional de Psiquiatria Ramon de la Fuente and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Panamerican Journal of Neuropsychology / Cuadernos de Neuropsicología is the property of Cuadernos de Neuropsicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Our objective was to evaluate levels of trait and state anxiety in a group of peri- and postmenopausal women and to explore the relation of hormonal therapy to levels of anxiety. Peri- (n = 63) and postmenopausal (n = 236) women were evaluated between March and September 2013. The assessed variables were menopausal status, anxiety (using the state and trait anxiety inventory), and sociodemographic and clinical variables. Use of psychotropic medications and hormone therapy was also ascertained. The mean age of the participants was 51.9 years, ranging from 31 to 69 years. The mean state anxiety scores, as well as the mean trait anxiety scores, were higher in perimenopausal than postmenopausal women. High state anxiety (above the 75th percentile), but not high trait anxiety, was related to perimenopausal status. Anxiety levels appeared to be higher among perimenopausal than postmenopausal women, as also occurs with depressive symptoms. Anxiety state provides data about recent anxiety symptoms in women; however, anxiety trait could be present in some women before perimenopause. Our findings suggest that perimenopause is a period with increased anxiety levels in some women. [ABSTRACT FROM PUBLISHER]